After FDA setback, psychedelic drugmakers distance themselves from a pioneer

Written By Nathan Sepeda

Dr. David Yaden offers his perspective on the “real risks and benefits of psychedelics” after the FDA’s rejection of MDMA for the treatment of PTSD. He hopes that public sentiment will become more “balanced and nuanced” regarding the state of evidence on psychedelics as medicine.

Nathan Sepeda
Previous

The State of Psychedelics
Next

Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics